Herbison Harriet, Davis Sidney, Nickless David, Haydon Andrew, Ameratunga Malaka
Department of Medical Oncology, Monash Health, Clayton, Victoria, Australia.
Department of Radiation Oncology, The Alfred Hospital, Melbourne, Victoria, Australia.
J Immunother Precis Oncol. 2024 Feb 5;7(1):67-72. doi: 10.36401/JIPO-23-19. eCollection 2024 Feb.
NUT carcinomas (NCs) are a group of rare tumors that can occur anywhere in the body and are defined by the fusion of the nuclear protein in testis () resulting in increased transcription of proto-oncogenes. NCs have a poor prognosis that varies according to the site of origin with an urgent need to develop new treatment strategies. Case reports on immunotherapy in pulmonary NC have been published, and bromodomain and extraterminal (BET) inhibitors have shown activity in NC in phase I/II trials. We present the case of a 27-year-old woman with an unresectable sinonasal NC who had a sustained clinical response to both immunotherapy and BET inhibitor therapy. This is the first reported case of immunotherapy in sinonasal NC, and it highlights the different responses to a range of treatments including BET inhibitor therapy. This case supports the theory that NCs arising from different primary sites have differing prognoses.
NUT癌（NCs）是一组罕见肿瘤，可发生于身体任何部位，其定义为睾丸核蛋白（）融合导致原癌基因转录增加。NCs预后较差，根据起源部位而异，迫切需要开发新的治疗策略。关于肺NC免疫治疗的病例报告已发表，溴结构域和额外末端（BET）抑制剂在I/II期试验中已显示对NC有活性。我们报告一例27岁患有不可切除鼻窦NC的女性病例，该患者对免疫治疗和BET抑制剂治疗均有持续临床反应。这是鼻窦NC免疫治疗的首例报告病例，它突出了对包括BET抑制剂治疗在内的一系列治疗的不同反应。该病例支持了源于不同原发部位的NCs预后不同的理论。
